Citalopram


Selective serotonin reuptake inhibitor

A racemic phthalane SSRI; the most selective for SERT over NET in clinical use.

Abstract

Citalopram (1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile; CAS 59729-33-8; molecular formula C20H21FN2O; molecular weight 324.39) is a bicyclic phthalane SSRI developed at H. Lundbeck in Denmark and approved in Europe in 1989 and by the FDA in 1998 under the trade name Celexa. The compound is sold as the racemate; the (S)-enantiomer (escitalopram) accounts for essentially all SERT inhibitory activity, while the (R)-enantiomer is largely inactive but may attenuate the (S)-enantiomer’s binding through allosteric SERT interaction. SERT affinity ((S)-enantiomer): Ki approximately 1 nM; selectivity over NET and DAT exceeds 1000-fold, making citalopram the most selective SSRI in clinical use. Plasma half-life is 33 to 37 hours; hepatic metabolism via CYP2C19, CYP3A4, and CYP2D6 produces minimally active metabolites. Used as the canonical selective SERT inhibitor in mechanism studies and as a reference compound in SSRI structure-activity work.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph